JP2018522567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522567A5 JP2018522567A5 JP2018506286A JP2018506286A JP2018522567A5 JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5 JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- specific
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069615A JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202698P | 2015-08-07 | 2015-08-07 | |
| US62/202,698 | 2015-08-07 | ||
| PCT/US2016/045360 WO2017027291A1 (en) | 2015-08-07 | 2016-08-03 | Bispecific car t-cells for solid tumor targeting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Division JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522567A JP2018522567A (ja) | 2018-08-16 |
| JP2018522567A5 true JP2018522567A5 (enExample) | 2019-09-12 |
| JP7162530B2 JP7162530B2 (ja) | 2022-10-28 |
Family
ID=57984403
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506286A Active JP7162530B2 (ja) | 2015-08-07 | 2016-08-03 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458167B2 (enExample) |
| EP (1) | EP3331920A4 (enExample) |
| JP (3) | JP7162530B2 (enExample) |
| CN (1) | CN108174604B (enExample) |
| AU (2) | AU2016306209B2 (enExample) |
| CA (1) | CA2994829A1 (enExample) |
| HK (1) | HK1256087A1 (enExample) |
| MX (1) | MX2018001568A (enExample) |
| WO (1) | WO2017027291A1 (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| JP7189019B2 (ja) | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたｔ細胞の投与 |
| SG11201807489PA (en) * | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
| WO2018111763A1 (en) | 2016-12-12 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US12496310B2 (en) | 2017-06-30 | 2025-12-16 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
| WO2019006464A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER |
| WO2019006465A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY AGAINST CANCER |
| AU2018309735B2 (en) * | 2017-07-31 | 2025-03-13 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
| CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
| KR102742741B1 (ko) | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) * | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| US11802163B2 (en) | 2017-11-10 | 2023-10-31 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting glypican-3 or mesothelin |
| US12139522B2 (en) | 2017-12-05 | 2024-11-12 | The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| WO2019111249A1 (en) | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| CN109970867B (zh) * | 2017-12-28 | 2022-10-18 | 上海细胞治疗研究院 | 一种cd40双向激活共刺激分子受体及其用途 |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| CN109970866B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd28双向激活共刺激分子受体及其用途 |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| CA3088161A1 (en) * | 2018-01-11 | 2019-07-18 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
| US12448426B2 (en) * | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| MX2020013621A (es) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Composiciones y metodos de tratamiento de vih. |
| KR20210031898A (ko) * | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
| CN108948211B (zh) | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| AU2019315440B2 (en) * | 2018-07-30 | 2025-03-13 | Angeles Therapeutics, Inc. | Improving the efficacy and safety of adoptive cellular therapies |
| CA3106544A1 (en) * | 2018-08-08 | 2020-02-13 | Mitchell Ho | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| SG11202102012SA (en) * | 2018-08-28 | 2021-04-29 | Pharos Vaccine Inc | Improved lentiviral vector |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| EP3868783A4 (en) * | 2018-10-19 | 2022-01-19 | Cartexell Inc. | ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院（山西医学科学院） | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
| CN113272320A (zh) * | 2018-11-19 | 2021-08-17 | 得克萨斯大学体系董事会 | 自杀基因 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| AU2019397152A1 (en) * | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20210129125A (ko) | 2019-02-20 | 2021-10-27 | 시티 오브 호프 | Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도 |
| WO2020190925A1 (en) | 2019-03-19 | 2020-09-24 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions for engineering cd4-deficient car t cells and anti-cd4 car t cells and uses thereof |
| CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
| WO2020210768A1 (en) * | 2019-04-12 | 2020-10-15 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| BR112021021608A2 (pt) * | 2019-04-30 | 2021-12-21 | Atara Biotherapeutics Inc | Células car-t direcionadas a cd19 específicas para antígeno |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| WO2020227446A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| WO2020227447A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
| JP7686574B2 (ja) | 2019-05-22 | 2025-06-02 | マサチューセッツ インスティテュート オブ テクノロジー | 環状ｒｎａ組成物及び方法 |
| AU2020286471B2 (en) * | 2019-06-07 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Dual CAR expressing T cells individually linked to CD28 and 4-1BB |
| BR112022001194A2 (pt) * | 2019-07-24 | 2022-06-07 | Regeneron Pharma | Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos |
| AU2020320129A1 (en) | 2019-07-30 | 2022-03-03 | University Health Network | T cell receptors and methods of use thereof |
| WO2021019472A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | T cell receptors and methods of use thereof |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| EP4054602A4 (en) * | 2019-11-08 | 2023-12-06 | Mayo Foundation for Medical Education and Research | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS |
| WO2021108670A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| MX2022006854A (es) * | 2019-12-04 | 2022-11-30 | Orna Therapeutics Inc | Composiciones y metodos de arn circular. |
| WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| CN113106067B (zh) * | 2020-01-10 | 2024-06-21 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| EP3892720A1 (en) * | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| EP4138864A4 (en) * | 2020-04-23 | 2024-07-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Polyspecific binding molecules and their use in cell therapy |
| WO2021226063A1 (en) | 2020-05-05 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Car comprising cd28 zeta and cd3 zeta |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| WO2021252358A1 (en) * | 2020-06-08 | 2021-12-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-cd171 chimeric antigen receptors |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| US20240307539A1 (en) * | 2020-09-30 | 2024-09-19 | Institute Of Zoology, Chinese Academy Of Science | Egfr-targeting chimeric antigen receptor |
| US20240043544A1 (en) * | 2020-12-08 | 2024-02-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| EP4259285A4 (en) * | 2020-12-09 | 2024-12-11 | Affyimmune Therapeutics, Inc. | DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1 |
| CN114685683B (zh) * | 2020-12-31 | 2025-07-08 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4394043A4 (en) * | 2021-08-24 | 2025-09-03 | Cells & Genes Biotech Shanghai Co Ltd | CELL MODIFICATION METHOD |
| EP4476267A4 (en) * | 2022-02-11 | 2026-01-07 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGENIC RECEPTORS BINDING TO STEAP1 |
| JP2025508961A (ja) * | 2022-03-03 | 2025-04-10 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 抗ＣＤ１９および抗ＣＤ７９ｂキメラ抗原受容体ならびにその使用方法 |
| CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
| WO2024131970A1 (zh) * | 2022-12-24 | 2024-06-27 | 深圳市菲鹏生物治疗股份有限公司 | 细胞组合物及其应用和药物 |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2025029484A1 (en) * | 2023-07-31 | 2025-02-06 | Bio4T2, Llc | Methods of blood cell-mediated in vivo car cell expansion and engraftment |
| CN117338914B (zh) * | 2023-10-27 | 2024-09-06 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
| WO2025113671A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海邦耀生物科技有限公司 | Car、表达car的细胞及其用途 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| EP0650367A4 (en) | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| AU2001270252B2 (en) | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| US20050004017A1 (en) | 2001-09-18 | 2005-01-06 | Yuval Reiss | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| CA2481509A1 (en) | 2002-04-11 | 2003-10-23 | Suzanna Tatarewicz | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US20040115814A1 (en) | 2002-09-30 | 2004-06-17 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| US20040158329A1 (en) | 2003-02-10 | 2004-08-12 | Waldemar Link (Gmbh & Co.) | Hip joint prosthesis with shaft inserted into femur |
| US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| EP1649020B1 (en) | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| US20070087346A1 (en) | 2003-10-24 | 2007-04-19 | Gennaro Ciliberto | Orthogonal gene switches |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| JP2009521474A (ja) * | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| EP2019860A4 (en) | 2006-05-22 | 2010-12-15 | Hiprocell Llc | PROTEIN PRODUCTION USING EUKARYOTIC CELL LINES |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| CN101828113B (zh) | 2007-07-25 | 2014-04-16 | 德国弗劳恩霍夫协会债权安格万特学术研究所 | 自结合重组抗体融合蛋白 |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DK2346995T3 (en) | 2008-09-26 | 2019-02-11 | Tocagen Inc | GENETERIVE VECTORS AND CYTOSINDEAMINASES |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| US20100332417A1 (en) | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| EP3115373B1 (en) | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| EP3683319A1 (en) | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| PL2723773T3 (pl) | 2011-06-22 | 2018-07-31 | F.Hoffmann-La Roche Ag | Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| WO2013181440A1 (en) | 2012-05-30 | 2013-12-05 | Baylor College Of Medicine | Supercoiled minivectors as a tool for dna repair, alteration and replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| US9792559B2 (en) | 2012-06-01 | 2017-10-17 | Nec Corporation | Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program |
| LT2884999T (lt) * | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US20160250258A1 (en) * | 2013-10-31 | 2016-09-01 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| EP3858379A1 (en) * | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| JP6682509B2 (ja) | 2014-05-14 | 2020-04-15 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球 |
| ES2836743T3 (es) | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| WO2016149578A1 (en) * | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| ES2958720T3 (es) | 2015-06-10 | 2024-02-13 | Immunitybio Inc | Células NK-92 modificadas para tratar el cáncer |
| CA3172801A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| MX2018001568A (es) * | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| JP7189019B2 (ja) | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたｔ細胞の投与 |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| US10626187B2 (en) | 2016-09-28 | 2020-04-21 | Kite Pharma, Inc. | Antigen binding molecules specific for an anti-CD19 scFv |
| DK3757120T3 (da) | 2016-10-04 | 2022-07-25 | Prec Biosciences Inc | Co-stimulerende domæner til anvendelse i genetisk modificerede celler |
| WO2018111763A1 (en) | 2016-12-12 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| BR102018008260A2 (pt) | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2016
- 2016-08-03 MX MX2018001568A patent/MX2018001568A/es unknown
- 2016-08-03 AU AU2016306209A patent/AU2016306209B2/en not_active Ceased
- 2016-08-03 CN CN201680058143.5A patent/CN108174604B/zh not_active Expired - Fee Related
- 2016-08-03 WO PCT/US2016/045360 patent/WO2017027291A1/en not_active Ceased
- 2016-08-03 CA CA2994829A patent/CA2994829A1/en active Pending
- 2016-08-03 JP JP2018506286A patent/JP7162530B2/ja active Active
- 2016-08-03 US US15/750,708 patent/US11458167B2/en active Active
- 2016-08-03 HK HK18115149.8A patent/HK1256087A1/zh unknown
- 2016-08-03 EP EP16835650.9A patent/EP3331920A4/en active Pending
-
2020
- 2020-11-03 US US17/088,005 patent/US11123369B2/en active Active
-
2022
- 2022-04-20 JP JP2022069615A patent/JP7566817B2/ja active Active
- 2022-09-12 US US17/931,258 patent/US20230130938A1/en active Pending
-
2023
- 2023-10-05 AU AU2023241321A patent/AU2023241321A1/en not_active Abandoned
-
2024
- 2024-10-02 JP JP2024172910A patent/JP2025000906A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11123369B2 (en) | Bispecific CAR T-cells for solid tumor targeting | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7267321B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| JP7862304B2 (ja) | Ｐｒａｍｅ ｔｃｒ受容体及びその使用 | |
| Park et al. | Treating cancer with genetically engineered T cells | |
| JP7221213B2 (ja) | 多官能性タンパク質 | |
| ES2732067T3 (es) | Receptor de antígeno quimérico (CAR) que contiene un dominio de unión a CD19 | |
| ES2681948T3 (es) | Células de acoplamiento para inmunoterapia | |
| ES2786263T3 (es) | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico | |
| US11890302B2 (en) | Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains | |
| ES2833162T5 (es) | Receptor de antígeno quimérico y su uso | |
| WO2022033537A1 (zh) | 工程化免疫细胞及其用途 | |
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| US20250002855A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| JP2015509717A (ja) | 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用 | |
| JP2024054286A (ja) | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 | |
| Golubovskaya | CAR-T cells targeting immune checkpoint pathway players | |
| WO2022223049A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| CN120623314A (zh) | 识别kras g12v抗原短肽的t细胞受体、复合物、药物组合物及用途 | |
| JP2025506515A5 (enExample) | ||
| WO2023035947A1 (zh) | 工程化免疫细胞及其用途 | |
| Kebriaei et al. | CARs: driving T-cell specificity to enhance anti-tumor immunity | |
| CN116103239A (zh) | 工程化免疫细胞及其用途 |